IPSC (Century Therapeutics) Earnings per share growth rate in current year

The annual growth rate of net income per share, as illustrated by the GURU.Markets terminal chart, reflects the struggle for leadership in clinical trials for Century Therapeutics (IPSC). The business relies on a unique gene-editing system that blocks copy expansion. The production of mass-market drugs from iPSC cells makes treatment predictable and accessible. The value of -271.00 indicates the level of this metric, determining the issuer's real valuation.

IPSC: Century Tx Earnings per share growth in current year 07/04/2022 - 11/15/2026

Financial and market metric breakdowns for Century Tx (IPSC)

- price and consensus price forecast:

Stock Quotes Century Tx|IPSC - Analyst Consensus Forecast

- business market valuation indicators:

Market Value Century Therapeutics, Inc.|IPSC - Total Company Value

- balance sheet equity data:

Net Assets per Single Share Century Therapeutics|IPSC - Company Book Value|Market Value to Book Value Ratio centurytx.com|IPSC - Cumulative Company Assets

- debt and liquidity details:

- earnings and valuation multiples information:

IPSC - Net Income|Expected Net Income Century Therapeutics|IPSC - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Century Tx|IPSC - PEG Multiple|Business Value to Operating Income Before Depreciation Century Therapeutics|IPSC - Operating profit EBITDA|Net earnings per one share for the last twelve months Century Therapeutics|IPSC - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months centurytx.com|IPSC - Earnings growth in current year|Earnings growth forecast for next year Century Therapeutics

- revenue and sales proceeds data:

IPSC - Company Revenue|Company Expected Revenue Century Therapeutics|IPSC - Market Cap to Revenue|Market Cap to Future Revenue Ratio Century Therapeutics|IPSC - Sales Growth YoY (TTM)

Fundamental valuation:IPSC centurytx.com

Manufactured products of Century Therapeutics, Inc.

Century Therapeutics focuses on a long-term R&D strategy and the development of cellular platforms guided by a strong scientific core. The eps_yy_co metric measures the annual percentage change in net income per share, reflecting the growth or decline rates of profitability. This metric allows an investor to identify value traps in a timely manner and assess operational efficiency. The current value of -271.00 serves as an indicator of market consensus. By analyzing the EPS YoY dynamics, one can forecast the sustainability of the company's capital.

Main competitors